SCHEMBL22208148

SCHEMBL22208148

Cc1cccc2cncc([Sn](C)(C)C)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CYP2A6 P11509 1/20 0.33
CYP1A2 P05177 1/20 0.33
ACHE P22303 4/20 0.32
ELANE P08246 3/20 0.32
PARP1 P09874 1/20 0.32
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
BCHE P06276 3/20 0.31
GRIN1 Q05586 3/20 0.31
GRIN2A Q12879 3/20 0.31
ROCK2 O75116 4/20 0.31
ROCK1 Q13464 3/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065085 1.00 KDM4E (0.34) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL29975520 0.80 NOS1 (0.34) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL22208149 0.80 NOS1 (0.34) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL8404527 0.78 CYP1A2 (0.41) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL18495139 0.75 ACHE (0.39) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL19070906 0.73 C1R (0.36) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL22208068 0.73 KDM4E (0.41) KDM4EALDH1A1CYP2A6CYP1A2ELANE
SCHEMBL18495138 0.73 BDKRB2 (0.38) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL17278414 0.73 CYP3A4 (0.41) KDM4EALDH1A1CYP2A6CYP1A2ACHE
SCHEMBL30545258 0.73 ALDH1A1 (0.38) KDM4EALDH1A1CYP2A6CYP1A2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 EP disclosed
EP-3908283-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-11-17 EP disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 US disclosed
WO-2020146613-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS KDM4E 3689/4885ALDH1A1 3370/4885CYP2A6 3834/4885
US-20200331911-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS KDM4E 3689/4885ALDH1A1 3370/4885CYP2A6 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.